Background Docetaxel and gemcitabine are active against breast cancer. The purpose of this phase II study was to evaluate the efficacy and safety of monthly docetaxel combined with weekly gemcitabine in patients with chemotherapy-pretreated metastatic breast cancer
Introduction
Metastatic breast cancer occurs commonly, despite recent advances in adjuvant therapy. Responses to chemotherapy, while frequent, may be short-lived, and the median survival for patients treated with chemotherapy for metastatic disease ranges between 18 and 24 months [1, 2] . The introduction of new agents has improved prognosis in chemotherapy-pretreated patients [3] Docetaxel is one of the most active drugs against advanced breast cancer [4, 5], but the optimal dose and schedule have not been determined When given once every 21 days at doses of 60 [6] , 75 [5, 7-9], or 100 mg/m 2 [9-13], 38%-68% of evaluable patients respond to docetaxel, with more frequent responses observed at the higher dose level Studies of weekly docetaxel schedules demonstrate a 35% response rate in advanced breast cancer [14] , with dose-limiting neuropathy [14] or diarrhea [15] rather than neutropenia. No studies of a docetaxel cycle length exceeding 21 days have been performed Gemcitabine, given on a weekly x 3 schedule, is another active drug against chemotherapy-naive and chemotherapy-pretreated breast cancer with response rates of 12%-33% [16] [17] [18] [19] [20] The quality of responses to this drug is remarkable, with some authors reporting response durations exceeding 12 months [16] [17] . In previous monotherapy trials [16] [17] [18] [19] [20] [21] , the day 1, 8 and 15 gemcitabine doses ranged from 800 to 1200 mg/m 2 , with no suggestion of a dose-response relationship.
Gemcitabine pretreatment has been shown to impair DNA repair mechanisms, resulting in enhanced effect of radiation and chemotherapy. Because of such a potential interaction and because of non-overlapping toxicity profiles, gemcitabine-docetaxel doublets have been developed [22] [23] [24] In a previous phase I study, we demonstrated that gemcitabine 800 mg/m 2 administered on days 1, 8, and 15 of a 28-day cycle could be safely combined with docetaxel 100 mg/m 2 on day 1 Encouraging antineoplastic activity was observed, consisting of partial responses in 4 of 7 patients with heavily pretreated metastatic breast cancer [22] . We theorized that combining these two drugs might link the high docetaxel response rate with the gemcitabine response durability, and that the longer dosing interval might circumvent the cumulative dose-limiting toxicities of docetaxel Therefore, we conducted the present phase II study, to assess the efficacy and safety of monthly docetaxel, combined with weekly gemcitabine, in patients with metastatic breast cancer who had received prior chemotherapy.
Patients and methods

Eligibility
Women with histologically confirmed metastatic breast cancer, failing prior chemotherapy in the adjuvant, metastatic, or both settings, with no previous exposure to gemcitabine or taxanes, were eligible Only one prior regimen for metastatic disease was allowed All patients had bidimensionally measurable disease They also had adequate marrow, hepatic, and renal function, with an absolute neutrophil count (ANQ of 1500/ul or greater, platelet count of 100,000/ul or greater, total bihrubin level equal to institutional upper limit of normal (ULN) or less, transaminase levels (AST and ALT) 1 5-fold or less than ULN. alkaline phosphatase level 2 5-fold of ULN or less, peripheral neuropathy no worse than grade 2, serum creatinine level 2 0 mg/dl or less, and a Southwest Oncology Group performance status (PS) of 0-2 All patients were informed of the investigational nature of the study and written informed consent was obtained This phase II trial was approved by the Clinical Research Committee and Institutional Review Board of the Columbus Community Clinical Oncology Program (CCOP)
Pretreatment and follow-up evaluations
On study entry, all patients had a complete history and physical examination, performance status evaluation, complete blood cell count with differentials, serum chemistries, and baseline tumor measurements Patients were evaluated weekly for toxicities Responses were assessed after the second and fourth treatment cycle, and every three cycles thereafter Continuation of chemotherapy beyond the fourth cycle for responders and patients with stable disease was left to the discretion of the investigators and patients, with no maximal number of cycles specified
Treatment plan
Gemcitabine 800 mg/m 2 was administered as a 30-min intravenous (I v) infusion, days 1, 8, and 15, of a 28-day cycle Docetaxel 100 mg/m 2 was administered as a one-hour infusion after gemcitabine on day 1 Both drugs were given in the outpatient setting, using five oral dexamethasone doses of 8 mg every 12 hours, starting 24 hours prior to docetaxel Anti-emetics were not used routinely Prophylactic oral antibiotics were recommended during periods of grade 3-4 neutropenia Prophylactic colony-stimulating factors were not used in the first cycle, but were allowed in subsequent cycles for patients who experienced either febrile neutropema, or grade 4 neutropenia lasting for seven or more days Within a cycle, the day 8 and day 15 doses of gemcitabine were reduced by 25%. if, on the day of treatment, the ANC was 500-999/ul or the platelet count was 50,000-74,000/ul Gemcitabine was omitted for an ANC less than 500/ul or a platelet count less than 50,000/ul Docetaxel was omitted if, on the day of treatment, ANC was less than 1500/ul, or the platelet count was less than 75,000/ul. or the total bihrubin greater than ULN. or if the transaminases or alkaline phosphatase values were greater than I 5-fold ULN and 2 5-fold ULN, respectively
The doses for both gemcitabine and docetaxel were permanently reduced by 25% if dose-limiting toxicities occurred in preceding cycles, including febrile neutropenia, grade 4 neutropenia lasting for seven or more days, platelet nadirs less than 20,000/ul, any grade 4 nonhematologic toxicities, and grade 3 non-hematologic toxicities persisting for more than four weeks, excepting asthenia
Response and toxicity criteria
Standard criteria were used for assessments of response, efficacy and toxicity, and all patients were included in the calculations Complete response (CR) was defined as resolution of all disease, for a minimum of four weeks Partial response (PR) was defined as equal to, or greater than 50% reduction in the sum of the products of the longest perpendicular diameters of measurable lesions, and without appearance of new lesions, lasting at least four weeks Responses were defined as durable if the anti-neoplastic effect persisted more than six months from treatment initiation Progressive disease (PD) was defined as equal to, or greater than 25% increase in the sum of the products of perpendicular diameters of measurable lesions, or the appearance of new lesions Stable disease (SD) was designated for all patients not qualifying for CR, PR Stable disease was defined as durable if lasting more than six months from treatment initiation All response assessments were confirmed independently by a non-treating physician (JPK)
Toxicity was graded according to standard National Cancer Institute common toxicity criteria
Statistical methods
This phase II study was designed to detect a response rate of at least 20% A two-stage design was used, with initial enrollment of 20 patients, and subsequent accrual of 20 more patients if one or more responses were observed in the initial cohort [25] The regimen would be considered worthy of further study if eight or more confirmed responses were observed, with acceptable toxicity The secondary end point was overall survival, which was calculated from the first day of treatment to the date of death Survival curves were estimated by the product-limit method [26] with log-rank comparisons Received dose intensities were calculated by the method of Hryniuk et al [27] 
Results
Patient accrual
Between February 1998 and November 1999, 39 patients with metastatic breast cancer were enrolled. Efforts to enroll the 40th patient by May 2000 were unsuccessful, for no discernable cause, so a decision was made to suspend accrual, and to close the study with 39 patients. Data analysis is current as of March 2001. Oncologists from five separate practices in central Ohio participated, under the auspices of the Columbus Community Clinical Oncology Program (CCOP).
Patient characteristics
Characteristics of patients and their tumors are summarized in Table 1 . The median age was 52 years, and the great majority of patients had good performance status. Most patients had visceral metastases, with a median of two involved organ systems (range 1-4). Prior chemotherapy was given as adjuvant in 30 patients, for metastatic disease in seven, and in both settings in two; 37 patients had received prior cyclophosphamide, and 33 had prior anthracychnes. 
Dose delivery
A total of 211 cycles were delivered, with a median of five cycles per patient (range, less than one to ten cycles) Thirty seven patients (95%) received more than one cycle. Only four cycles were delayed for a week or longer, due to patient preference in three instances, and once for bronchitis. The mean delivered gemcitabine dose intensity was 380 mg/m 2 /week (63% of planned), and the mean delivered docetaxel dose intensity was 22 mg/m 2 /week (88% of planned). Intracycle dose delivery of gemcitabine is shown in Table 2 Of the 125 cycles given at full day 1 doses of docetaxel and gemcitabine, day 8 or day 15 gemcitabine was omitted 95 times, and dose-reduced 85 times, nearly always for neutropenia. Of the 59 cycles (21 patients) using 75% doses of docetaxel and gemcitabine on day 1, the delivery of day 8 and 15 gemcitabine was also limited by neutropenia, with 38 doses omitted and 22 decreased. Even in the 21 cycles (five patients) given at 56% dose docetaxel and gemcitabine on day 1, there were 11 dose omissions and 8 decreases, for neutropenia. A total of 11 patients (28%) received filgrastim, five during acute neutropenic episodes and six prophylactically following dose-limiting neutropenic events in preceding cycles. In the 16 cycles given with prophylactic filgrastim, only 2 of 32 intracycle gemcitabine doses were omitted, and 89% of planned gemcitabine dose was administered.
Toxicities
Toxicities observed during 211 cycles of chemotherapy are presented as the worst toxicity grade experienced by each patient (Table 3 ). The principal hematologic toxicity was neutropenia, with ANC nadirs less than 500/ul observed in 37 of 39 patients (46% of cycles). Only 6 of 211 cycles (3%) were complicated by febrile neutropenia, affecting 3 of the 39 patients. Three additional patients had documented non-neutropenic infections One filgrastim-treated patient experienced a single episode of severe thrombocytopenia, requiring transfusion of four platelet units Anemia was common but generally mild; three patients required transfusion of eight units of packed red blood cells, and one patient received weekly erythropoietin for four months.
The majority of patients experienced asthenia, which was grade 3 in 13 patients, requiring permanent dose reduction in one individual. Moderate-to-severe docetaxel-related fluid retention occurred in eight patients, and was manifested as pedal edema, worsening upper extremity lymphedema, and/or pleural effusion. It occurred after a minimum of 3 cycles, and affected half of the 12 patients receiving 7 or more cycles Fluid retention was responsive to thiazide and loop diuretics, and resolved after discontinuation of docetaxel. The four patients who experienced grade 3 fluid retention during cycles 5, 5, 7, and 7, were able to receive a total of 7, 8, 8, and 7 cycles, respectively.
Severe nausea and emesis were infrequent, with only three brief episodes occurring in two patients Flu-like symptoms of chills, rigors, fevers, malaise, arthralgias and myalgias occurred in 36% of patients and were severe in 5%. These symptoms occurred within 24-48 hours after the gemcitabine infusions and could be ameliorated during subsequent courses with diphenhydramine and hydrocortisone pretreatment. One patient had two episodes of severe dizziness immediately following gemcitabine administration, causing her to withdraw from the trial.
Skin toxicity was mild and consisted of maculopapular erythematous eruptions in 14 patients (36%), and palmar plantar erythrodysesthesia in one, possibly related to prior therapy. Nail ridging and dark discoloration were common, and alopecia was universal. Grade 2 sensory neuropathy occurred in five patients, and three patients had sore throat or pharyngitis. Nearly all patients described altered taste, and 27 patients complained of anorexia. Grade 2 hepatic dysfunction, manifest as transient, asymptomatic transaminase elevation, occurred in two patients (5%). All patients had steroid-related symptoms, such as insomnia, heartburn, glucose intolerance, oral and vaginal candidiasis, hot flashes, or steroid-withdrawal symptoms of malaise or arthralgias
Efficacy
The overall response rate, analyzed on an intent-to-treat basis, was 79% (31 of 39, 95% CI. 63%-91%) There were two complete and 29 partial responses. Both complete responders and 23 of 29 partial responders remained progression-free for more than six months Of the 8 non-responders, 3 had stable disease lasting 4, 8, and 11+ months, 3 progressed, and 2 were not evaluable because they withdrew after the first dose of gemcitabine and docetaxel. Therefore, durable responses (CR or PR lasting more than 6 months) were seen in 64% of patients, whereas antineoplastic benefit (all CR, PR, and stable disease lasting more than six months) was seen in 84%). Response rates were high even in subgroups likely to have poor outcomes (Table 4) .
With a median potential follow-up period of 24.9 months and twenty deaths, the median survival duration for all 39 patients was 24.5 months (range, 5.7 to 34.2+ months). The actual one-year survival probability is 74%, with estimated two-year survival probability of 53%. There were no significant survival differences between the thirty patients who received prior chemotherapy in the adjuvant setting only, and the nine patients with prior chemotherapy for metastatic disease.
Discussion
The previously noted high response frequency to docetaxel, and the durability of responses to weekly x 3 gemcitabine, provided the incentive for combining the two drugs in patients with chemotherapy-pretreated metastatic breast cancer. To augment efficacy and treat responders for longer periods of time, the maximal single-agent docetaxel dose (100 mg/m 2 ) was given on a monthly basis in combination with an active gemcitabine schedule. Because 30-minute gemcitabine infusions at doses as low as 350 mg/m 2 are sufficient for maximal cellular formation of the active metabolite dFdCTP [28, 29], a major detrimental impact of intracycle gemcitabine dose reductions on the antitumor activity of this drug was considered unlikely. Therefore, the use of colony-stimulating factors for the sole purpose of maintaining dose intensity was not deemed necessary. Prolonging the gemcitabine infusion duration to achieve optimal dose rate (10 mg/m 2 /min) may further increase efficacy [30] , but the safety of fixed dose rate gemcitabine in combination with docetaxel remains uncertain [31] .
Efficacy outcomes appear to validate these concepts. The resulting intent-to-treat response rate of 79% noted in this trial is higher than any previously reported with these drugs, either alone or in combination [32] [33] It is more than twice that of gemcitabine alone, is higher than the best results with single agent docetaxel, and is higher than the 36% and 54% second-line response rates reported with the 21-day schedules of gemcitabine-docetaxel (Table 5 ). The high response rates obtained in patient subgroups with unfavorable prognosis, and the durability of antineoplastic effect further emphasize the activity of the combination. The survival statistics also compare favorably to those of other trials.
This antineoplastic effect was obtained despite delivering only 63% of planned gemcitabine dose intensity, mainly reflecting missed or decreased day eight doses. This was somewhat lower than the 75% of planned gemcitabine delivery noted in the phase I study, includ- Abbreviations DOC -docetaxel, GEM -gemcitabine, G-CSF -filgrastim, NA -non-applicable ing predominantly lung cancer patients [22] , and the 74% gemcitabine delivery in a second-line phase II trial of this doublet in 40 NSCLC patients [34] . These differences may be due to the prior anthracychne exposure in breast cancer patients. Although routine prophylactic use of colony-stimulating factors might have allowed better gemcitabine delivery, any resulting improvement upon an already high rate of durable responses would be probably marginal. High response rates may reflect chance, careful patient selection, as may occur in single-institution trials, or a true improvement in therapeutic efficacy. In this multicenter study, all responses were confirmed by a rigorous independent review. Pretreatment characteristics of these patients were comparable to those enrolled in similar trials and the presence of poor prognostic factors did not appear to compromise the probability for response.
Although formidable, neutropenia was only a laboratory observation for the great majority of patients. The incidence of severe neutropenia with this regimen was not appreciably worse than has been observed with docetaxel alone [5] . The low frequencies of neutropenic fever and infections (3% and 2% of all cycles, respectively) likely reflect the use of prophylactic antibiotics, lack of treatment-induced mucositis, and the experience of the treating physicians in managing neutropenic patients. It should be noted that in the 21-day gemcitabine-docetaxel studies, the routine use of filgrastim not only did not appear to decrease the frequency of febrile neutropenia (18% and 8% of patients vs. 8% in the present study), but it was also associated in one of the studies [31] with higher frequency (21% vs. 3% in present study) of severe thrombocytopenia. Other clinically relevant toxicities were easily managed. Asthenia was the most troublesome, but resolved quickly upon discontinuation of therapy Severe fluid retention was uncommon, even though the median number of cycles was five. This low incidence might be a result of steroid prophylaxis, prompt treatment, or, possibly, to the 28-day intervals between cycles.
One might ask whether the toxicities associated with this doublet are justified in patients with incurable cancer. Since asthenia, the most common patient complaint, was reversible upon discontinuation of therapy, it can be considered a reasonable trade-off for a high rate of durable responses and prolonged survival.
In conclusion, monthly docetaxel combined with weekly gemcitabine is highly active for chemotherapypretreated metastatic breast cancer, resulting in a substantial proportion of good quality responses, irrespective of baseline prognostic factors Neutropenia is substantial but manageable. The study was conducted by practicing oncologists in a community-based patient population, therefore the results may be generally applicable to similar settings. 
